Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants X Shi, R Liu, F Basolo, R Giannini, X Shen, D Teng, H Guan, Z Shan, ... The Journal of Clinical Endocrinology 101 (1), 264-274, 2016 | 236 | 2016 |
The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis W Liu, S Cheng, SL Asa, S Ezzat Cancer research 68 (19), 8104-8112, 2008 | 172 | 2008 |
Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation CD Simpson, IA Mawji, K Anyiwe, MA Williams, X Wang, AL Venugopal, ... Cancer research 69 (7), 2739-2747, 2009 | 121 | 2009 |
Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study C Ramírez, S Cheng, G Vargas, SL Asa, S Ezzat, B Gonzalez, L Cabrera, ... The Journal of Clinical Endocrinology 97 (5), 1745-1751, 2012 | 116 | 2012 |
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature S Cheng, L Grasso, JA Martinez‐Orozco, R Al‐Agha, R Pivonello, ... Clinical endocrinology 76 (2), 264-271, 2012 | 110 | 2012 |
A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior S Cheng, S Serra, M Mercado, S Ezzat, SL Asa Clinical Cancer Research 17 (8), 2385-2394, 2011 | 89 | 2011 |
Ectopic ACTH-secreting syndrome: a single center experience report with a high prevalence of occult tumor I Hernandez, AL Espinosa-de-los-Monteros, V Mendoza, S Cheng, ... Archives of Medical Research 37 (8), 976-980, 2006 | 63 | 2006 |
Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease M Mercado, AL Espinosa de los Monteros, E Sosa, S Cheng, V Mendoza, ... Hormone Research in Paediatrics 62 (6), 293-299, 2004 | 59 | 2004 |
Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status AL Espinosa‐de‐los‐Monteros, E Sosa, S Cheng, R Ochoa, C Sandoval, ... Clinical Endocrinology 64 (3), 245-249, 2006 | 58 | 2006 |
Osteopontin (OPN) expression in thyroid carcinoma J Briese, S Cheng, S Ezzat, W Liu, D Winer, C Wagener, AM Bamberger, ... Anticancer research 30 (5), 1681-1688, 2010 | 51 | 2010 |
GSPα mutations in Mexican patients with acromegaly: potential impact on long term prognosis V Mendoza, E Sosa, AL Espinosa-de-Los-Monteros, M Salcedo, G Guinto, ... Growth hormone & IGF research 15 (1), 28-32, 2005 | 46 | 2005 |
Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior E Morin, S Cheng, O Mete, S Serra, PB Araujo, S Temple, S Cleary, ... Cancer medicine 2 (5), 701-711, 2013 | 44 | 2013 |
Epigenetics of pituitary tumors: pathogenetic and therapeutic implications S Ezzat, S Cheng, SL Asa Molecular and Cellular Endocrinology 469, 70-76, 2018 | 42 | 2018 |
The role of diabetes in acromegaly associated neoplasia S Cheng, K Gomez, O Serri, C Chik, S Ezzat PLoS One 10 (5), e0127276, 2015 | 41 | 2015 |
Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors PB Araujo, S Cheng, O Mete, S Serra, E Morin, SL Asa, S Ezzat PloS one 8 (4), e61538, 2013 | 40 | 2013 |
The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression K Balogh, SL Asa, L Zheng, C Cassol, S Cheng, S Ezzat Oncogene 31 (36), 4012-4021, 2012 | 38 | 2012 |
Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer S Cheng, W Liu, M Mercado, S Ezzat, SL Asa Endocrine-Related Cancer 16 (2), 455, 2009 | 31 | 2009 |
Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide B Gonzalez, G Vargas, C Ramirez, S Asa, S Cheng, C Sandoval, ... Endocrinologia y Nutricion 61 (10), 523-530, 2014 | 20 | 2014 |
Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly S Cheng, R Al-Agha, PB Araujo, O Serri, S L. Asa, S Ezzat PLoS one 8 (9), e73543, 2013 | 16 | 2013 |
Cardiovascular risk factors in acromegaly: what's the impact of disease control? A Amado, F Araújo, D Carvalho Experimental and Clinical Endocrinology & Diabetes 126 (08), 505-512, 2018 | 13 | 2018 |